Romiplostim biosimilar(Eris Lifesciences)

N/A

Report date: 2025/03/07 17:34:30

Base Information

Drug NameRomiplostim biosimilar(Eris Lifesciences)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, Idiopathic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A